MTNB Matinas BioPharma Holdings, Inc.

Overview and Growth

In fiscal 2025, Matinas BioPharma Holdings, Inc. reported net loss of $10.35M. The company reported diluted EPS of -$2.00, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 5.47M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 12.5% from 4.87M in fiscal 2024, leaving the current share base higher year over year. Total assets stood at $7.21M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The reported operating result was an operating loss of $6.96M, reflecting costs that exceeded gross profit. After all below-operating-line items, the company recorded a net loss of $10.35M for the fiscal year. EBITDA was negative $6.93M, showing a deficit before interest, taxes, depreciation, and amortization. Before income taxes, the company recorded a loss of $10.35M, bridging the operating result to the final net loss. The loss-to-equity relationship was 214.2%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 143.5%. The net loss narrowed to $10.35M from $24.25M in fiscal 2024.

Liquidity and Capital Structure

Total assets were $7.21M, supported by $2.38M of liabilities and $4.83M of shareholder equity. Current assets were $4.08M against $1.46M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 2.79x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $4.00M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 273.3% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 67.0%, placing book capital against the total resource base. Relative to total assets, liabilities measured 33.0%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 55.5% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $12.64M in fiscal 2024, the current asset base moved 43.0% and finished lower. Book equity was 36.4% lower than fiscal 2024 equity of $7.59M, showing how shareholder capital changed year over year. Compared with $7.28M in fiscal 2024, the current cash balance moved 45.1% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $7.01M, showing that operations absorbed cash during the period. Cash absorbed by operations decreased from $15.88M in fiscal 2024 to $7.01M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.